[1] His research focuses on the development and application of novel functional molecular systems to a broad range of areas; from materials to medicine.

Fuchter earned a master's degree (MSci) in chemistry at the University of Bristol, where he was awarded the Richard Dixon prize.

[4] As a graduate student he moved to Imperial College London, where he worked with Anthony Barrett on the synthesis and applications of porphyrazines, including as therapeutic agents.

[2] After completing his PhD, Fuchter moved to Australia, for postdoctoral research at CSIRO and the University of Melbourne, where he worked with Andrew Bruce Holmes.

Fuchter has also developed novel molecular photoswitches – molecules that can be cleanly and reversibly interconverted between two states using light – with a focus on heteroaromatic versions of azobenzene.

[7][11] The drug, which was designed using computational chemistry, inhibits the cyclin-dependent kinase 7 (CDK7), a transcriptional regulatory protein that also regulates the cell cycle.